Renaissance Capital logo

ASPX News

Ice Buckets and IPOs: 6 biotechs targeting CNS diseases

The ALS Association issued a press release Tuesday stating that donations in the past month have reached $89 million, including $66 million in the past...read more

Renaissance Capital's 1Q 2014 US IPO Quarterly Review

The US IPO market showed more activity than any other first quarter since 2000 as 64 companies raised $10.6 billion. That is more than double the number of IPOs in the first quarter of 2013, a year that also had the most public offerings in over a decade. IPO...read more

CNS disorders pharmaceutical Adamas Pharmaceuticals sets terms for $51 million IPO

Adamas Pharmaceuticals, which develops treatments for CNS disorders such as Parkinson's and Alzheimer's, announced terms for its IPO on Wednesday. The Emeryville, CA-based company plans to raise $51 million by offering 3.0 million shares at a price range of $16...read more

Orphan disease biotech Versartis upsizes IPO and increases range to $19 to $21

Versartis, a biotech developing long-acting treatments for growth hormone deficiency, raised the proposed deal size for its upcoming IPO on Wednesday. The Redwood City, CA-based company now plans to raise up to $126 million by offering 6.0 million shares at a...read more